Steven Le Gouill

22PUBLICATIONS
113CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Oct 22, 2025
Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry.

Federico Erbella, Emmanuel Bachy, Guillaume Cartron

|Sep 30, 2025
Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.

Marion Aymard, Morgane Cheminant, Roch Houot

|Sep 18, 2025
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Sarah Cayla, Lionel Karlin, Jérôme Lambert

|Aug 04, 2025
Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.

Olivier Tournilhac, Kamal Bouabdallah, Solène Lecolant

|May 29, 2025
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches.

Toby A Eyre, Chan Y Cheah, Clémentine Sarkozy

|May 01, 2025
TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas.

Pierre Stephan, Roberta Di Blasi, Louise Roulin

Pageof 4

Frequent Collaborators

11 joint publications

Franck Morschhauser

11 joint publications

Roch Houot

9 joint publications

Emmanuel Bachy

8 joint publications

Guillaume Cartron